View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Alvotech signs U.S. agreement to expand access for newly approved high...

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira® The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally REYKJAVIK, Iceland, April 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the de...

 PRESS RELEASE

Alvotech signs U.S. agreement to expand access for newly approved high...

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for p...

 PRESS RELEASE

Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahlið...

Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi eykst útbreiðsla hliðstæðunnar í Bandaríkjunum og aðgengi sjúklinga að hagkvæmari líftæknilyfjum  Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hefði gert langtímasamning við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu og markaðssetningu á adalimumab-ryvk, fyrst...

Integrated Research Limited: 1 director

A director at Integrated Research Limited bought 260,000 shares at 0.378AUD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

WiseTech Global Limited: 2 directors

Two Directors at WiseTech Global Limited sold 226,030 shares at 89.280AUD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

Genetics holding back growth short-term

Flat organic sales growth, due to Genetics. EBITDA revised down 1.5%-2.3% for '24e-'26e. 41-43% below historical multiples, but above sector peers.

 PRESS RELEASE

Man Group PLC : Form 8.3 - Barratt Developments plc

Man Group PLC : Form 8.3 - Barratt Developments plc FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant secur...

Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/NBFI's liquidity preparedness, no S&P rating changes expec...

Financial Stability Board on Non-Bank Financial Institutions' liquidity preparedness to margin and collateral calls. No rating upgrades expected at S&P for Icelandic covered bonds following the rating agency's systemic importance reassessment. UniCredit confirms to call the US$1.25bn AT1 in June, the bank can easily absorb the negative impact on its substantial MDA buffer

Fonix Mobile: 3 directors

Three Directors at Fonix Mobile sold 6,666,667 shares at 225p. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

Man Group PLC : Form 8.3 - International Paper Company

Man Group PLC : Form 8.3 - International Paper Company FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant se...

Matthias Desmarais
  • Matthias Desmarais
 PRESS RELEASE

Man Group PLC : Form 8.3 - Mondi plc

Man Group PLC : Form 8.3 - Mondi plc FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form...

 PRESS RELEASE

Form 8.3 - UK Commercial Property REIT

Form 8.3 - UK Commercial Property REIT 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this f...

Solutiance AG: 1 director

A director at Solutiance AG sold 100,000 shares at 2.000EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Bob Liao
  • Bob Liao

Audio Note: Devolver Digital - Rebuild year

In this audio note, Zeus’ Bob Liao summarises the investment case for Devolver Digital. Devolver Digital encouragingly delivered 2023 results slightly ahead of expectations and provided a steady medium-term outlook that leads us to reiterate our 2024 Adjusted EBITDA estimates. Listen to the audio note below, and read the full research here.

Bob Liao
  • Bob Liao

Audio Note: CyanConnode - FY24 update: revenue materially ahead

In this audio note, Zeus’ Bob Liao summarises the investment case for CyanConnode. CyanConnode exceeded FY24 revenue expectations and has high visibility into FY25, supported by strong deliveries and a growing backlog respectively. Listen to the audio note below, and read the full research here.

James Knightley
  • James Knightley

Watch: Why we've made big changes to our US outlook

We still think we'll get some interest rate cuts in America this year, but far fewer than we thought just months ago. Here's why our thinking's changed

Julie Boote ... (+2)
  • Julie Boote
  • Pelham Smithers

PSA Today 19 Apr: Israel Iran trouble spooks market / March inflation ...

PSA Today Japan Market Comment by Pelham Smithers and Julie Boote Tags: TSMC (2330 TT), Tokyo Electron (8035 JT), Lasertec (6920 JT), MHI (7011 JT), KHI (7012 JT), NEC Corp (6701 JT), Hitachi (6501 JT), Astellas (4503 JT), Chugai Pharmaceutical (4519 JT), Sakura Internet (3778 JT), KDDI (9433 JT), Shinko Electric (6967 JT), Nvidia (NVDA US), Advanced Micro Devices (AMD US), Nissan Motor (7201 JT) Main Points • Nikkei 225 drops 1,000+ points on Middle East, TSMC news • Japan inflation slows ...

Moody's Ratings affirms Union Bank of the Philippines' Baa2 ratings; o...

Moody's Ratings (Moody's) has today affirmed Union Bank of the Philippines' (UBP) Baa2 long-term (LT) local currency (LC) and foreign currency (FC) deposit ratings, Baa2 LT LC and FC issuer ratings, and Baa2 FC senior unsecured rating. Moody's has also maintained the negative outlook on these rating...

ABGSC Financials Research ... (+4)
  • ABGSC Financials Research
  • Albert Broock
  • Magnus Andersson
  • Patrik Brattelius

Q1'24: Improved exit activity key

Higher exit activity needed to defend estimates. Minor adj. EPS revisions for 2024e-26e. We keep our HOLD rating with a target price of SEK 280.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch